1-3 of 3
Hugh Xiao
Close
Sort by
Journal Articles

Results From a Phase 1 Multicenter Trial of Alisertib (MLN8237)–An Investigational Aurora A Kinase Inhibitor–in Patients with Advanced Hematologic Malignancies

Kevin R. Kelly, MD, Swaminathan Padmanabhan, MBBS, MD, André Goy, MD, Jesus G. Berdeja, MD, Craig B. Reeder, MD, Kevin T. McDonagh, MD, Xiaofei Zhou, PhD, Hadi Danaee, SD, Hugh Xiao, PhD, Ely Benaim, MD, Thomas C. Shea, MD
Journal: Blood
Blood (2011) 118 (21): 2477.
https://doi.org/10.1182/blood.V118.21.2477.2477
Published: 2011
Journal Articles

Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma

Clinical Trials & Observations
Sagar Lonial, Edmund K. Waller, Paul G. Richardson, Sundar Jagannath, Robert Z. Orlowski, Cynthia R. Giver, David L. Jaye, Dixil Francis, Sara Giusti, Claire Torre, Bart Barlogie, James R. Berenson, Seema Singhal, David P. Schenkein, Dixie-Lee W. Esseltine, Jessica Anderson, Hugh Xiao, Leonard T. Heffner, Kenneth C. Anderson, for the SUMMIT/CREST Investigators
Journal: Blood
Blood (2005) 106 (12): 3777–3784.
https://doi.org/10.1182/blood-2005-03-1173
Published: 2005
Journal Articles

Clinical factors predictive of outcome with bortezomib in patients with relapsed, refractory multiple myeloma

Clinical Trials & Observations
Paul Gerard Guy Richardson, Bart Barlogie, James Berenson, Seema Singhal, Sundar Jagannath, David Irwin, S. Vincent Rajkumar, Teru Hideshima, Hugh Xiao, Dixie Esseltine, David Schenkein, Kenneth C. Anderson, for the SUMMIT Investigators
Journal: Blood
Blood (2005) 106 (9): 2977–2981.
https://doi.org/10.1182/blood-2005-02-0691
Published: 2005